People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Hosted on MSN7d
FDA approves standalone nasal spray to treat depressionA one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
There was no effect of insulin in the larger cohort using the second device. In a subsequent Phase 2 study to determine how much insulin entered the brain after nasal delivery, 19 people received 40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback